Industry Watch

2009 ◽  
Vol 13 (12) ◽  
pp. 37-50
Keyword(s):  
Bone Marrow ◽  
Global Network ◽  
Asia Pacific ◽  
Disease Treatment ◽  
Target Drug Delivery ◽  
Target Drug ◽  
Healthcare Product ◽  
Target Drug Delivery System ◽  
Bone Marrow Regeneration ◽  
University Industry

CSIRO and Circadian Collaborate in Oncology R&D. Successful Trials in Bone Marrow Regeneration Using Cord Blood. Pfizer China and BMP Sunstone Venture into Women's Healthcare Product. Novartis Acquires Zhejiang Tianyuan to Expand Human Vaccines Presence in China. Carbon Nanotechnology for Target Drug Delivery System Launched in India. Cipla Launches Antiflu to Combat Influenza. Tokyo CRO and Ecron Acunova in Alliance to Strengthen Global Network. World's First Oral Jelly for Alzheimer's Disease Treatment. Leading Japanese and Swedish Biotech Firms Seal Antibody Deal. Caduet® Combination Tablets Launched in Japan. Spectrum Teams Up with Korea's Handok on Apaziquone. Biologics, CEVEC Sign Agreement for Using Human CAP Technology. Chaperone Technologies and MerLion Pharmaceuticals in Antimicrobials Collaboration. Quintiles Expands Asia-Pacific Headquarters in Singapore. NCKU and ScinoPharm Taiwan Establish University-Industry Cooperation.

Preparation and anti-cancer activity of transferrin/folic acid double-targeted graphene oxide drug delivery system

2020 ◽  
Vol 35 (1) ◽  
pp. 15-27 ◽  
Author(s):  
Taicheng Lu ◽  
Zhenzhen Nong ◽  
Liying Wei ◽  
Mei Wei ◽  
Guo Li ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Graphene Oxide ◽  
Folic Acid ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Drug Loading ◽  
Target Drug Delivery ◽  
Target Drug ◽  
Target Drug Delivery System

In this study, a transferrin/folic acid double-targeting graphene oxide drug delivery system loaded with doxorubicin was designed. Graphene oxide was prepared by ultrasound improved Hummers method and was modified with Pluronic F68, folic acid, and transferrin to decrease its toxicity and to allow dual-targeting. The results show that the double target drug delivery system (TFGP*DOX) has good and controllable drug delivery performance with no toxicity. Moreover, TFGP*DOX has a better inhibitory effect on SMMC-7721 cells than does a single target drug delivery system (FGP*DOX). The results of drug release analysis and cell inhibition studies showed that TFGP*DOX has a good sustained release function that can reduce the drug release rate in blood circulation over time and improve the local drug concentration in or near a targeted tumor. Therefore, the drug loading system (TFGP*DOX) has potential application value in the treatment of hepatocellular carcinoma.

scholarly journals TAT-modified serum albumin nanoparticles for sustained-release of tetramethylpyrazine and improved targeting to spinal cord injury

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Yan Lin ◽  
Yujie Wan ◽  
Xingjie Du ◽  
Jian Li ◽  
Jun Wei ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Spinal Cord ◽  
Drug Delivery System ◽  
Delivery System ◽  
Target Drug Delivery ◽  
Target Drug ◽  
Cord Injury ◽  
Target Drug Delivery System ◽  
Targeting Ability

Abstract Background Spinal Cord injury (SCI) is a kind of severe traumatic disease. The inflammatory response is a significant feature after SCI. Tetramethylpyrazine (TMP), a perennial herb of umbelliferae, is an alkaloid extracted from ligustici. TMP can inhibit the production of nitric oxide and reduce the inflammatory response in peripheral tissues. It can be seen that the therapeutic effect of TMP on SCI is worthy of affirmation. TMP has defects such as short half-life and poor water-solubility. In addition, the commonly used dosage forms of TMP include tablets, dropping pills, injections, etc., and its tissue and organ targeting is still a difficult problem to solve. To improve the solubility and targeting of TMP, here, we developed a nanotechnology-based drug delivery system, TMP-loaded nanoparticles modified with HIV trans-activator of transcription (TAT-TMP-NPs). Results The nanoparticles prepared in this study has integrated structure. The hemolysis rate of each group is less than 5%, indicating that the target drug delivery system has good safety. The results of in vivo pharmacokinetic studies show that TAT-TMP-NPs improves the bioavailability of TMP. The quantitative results of drug distribution in vivo show that TAT-TMP-NPs is more distributed in spinal cord tissue and had higher tissue targeting ability compared with other treatment groups. Conclusions The target drug delivery system can overcome the defect of low solubility of TMP, achieve the targeting ability, and show the further clinical application prospect.

Surface Modified Nanoparticulate Carriers for the Targeted Treatment of Breast Cancer

2015 ◽  
Vol 8 (1) ◽  
pp. 2698-2714
Author(s):  
Neeraj Mishra ◽  
Tejinder Singh ◽  
Nidhi ◽  
Supandeep Singh Hallan ◽  
Veerpal Kaur
Keyword(s):  
Breast Cancer ◽  
Tumor Targeting ◽  
Lipid Nanoparticles ◽  
Targeted Treatment ◽  
Therapeutic Effects ◽  
Target Drug Delivery ◽  
Target Drug ◽  
Therapeutic Outcomes ◽  
Lipid Nanocarriers ◽  
Surface Modified

Breast cancer left overs one of the greatest common metastasis disease in females. Advanced diagnostic devices and better understanding of tumour biology can extend the better therapeutic outcomes. Nanotechnology is a tool that helps in cancer diagnosis and treatment therapy. Many nanocarriers such as solid lipid nanoparticles, magnetic nanoparticles, nanocrystals, nanogels, nano-lipid nanocarriers, biodegradable nanoparticles, liposomes, and dendrimers are introduced to improve the therapeutic efficacy of antineoplastic agents. Surface modified target drug delivery system has the potential to increase the therapeutic effects and also reduce the cytotoxicity of breast cancer. Different approaches have been explored for treatment of breast cancer. This review describes the recent advances in the development of nanocarriers used for the targeted treatment of breast cancer. It also focuses on etiology, risk factor and conventional therapy of breast cancer. KEYWORDS: Breast Cancer; Nano-carriers; Tumor Targeting; Ligands; Receptor.

scholarly journals Clostridium haemolyticum Infection: A Cause of Hemolytic Anemia in a Patient with Bone Marrow Necrosis

2021 ◽  
Vol 9 (8) ◽  
pp. 1568
Author(s):  
Anne Sophie Lagneaux ◽  
Sandrine Hénard ◽  
Laure Diancourt ◽  
Emmanuelle Stein ◽  
Pierre Perez ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Hemolytic Anemia ◽  
Obese Woman ◽  
Molecular Techniques ◽  
Significant Past Medical History ◽  
Bone Marrow Necrosis ◽  
Rdna Sequencing ◽  
Oxygen Sensitive ◽  
Bacteremic Episode ◽  
Bone Marrow Regeneration

Clostridium haemolyticum is a sporulating Gram-positive anaerobic rod that is considered to be one of the most fastidious and oxygen-sensitive anaerobes. It is a well-known animal pathogen and the cause of bacillary hemoglobinuria primarily in cattle. To date, human infections caused by C. haemolyticum have been reported in three patients with malignant underlying diseases. We present herein the case of a 30-year-old obese woman with no significant past medical history who developed bacteremia caused by C. haemolyticum with massive intravascular hemolysis associated with bone marrow necrosis and acute renal failure. Because of subculture failure, the diagnosis was made on the basis of 16S rDNA sequencing and next-generation sequencing. The patient, who had been afebrile for 20 days after a 17-day-course of antibiotics, experienced a second bacteremic episode caused by C. haemolyticum. After having been successfully treated for 42 days with clindamycin and amoxicillin-clavulanic acid, the patient developed acute myeloid leukemia as a result of bone marrow regeneration. Although uncommon in humans, infections caused by C. haemolyticum are severe and should be considered in a febrile patient who has severe hemolytic anemia. This case also highlights the importance of using molecular techniques for the identification of this fastidious anaerobic organism.

scholarly journals Synthesis, Characterization, and Evaluation of a Novel Amphiphilic Polymer RGD-PEG-Chol for Target Drug Delivery System

2014 ◽  
Vol 2014 ◽  
pp. 1-10 ◽  
Author(s):  
Shi Zeng ◽  
Fengbo Wu ◽  
Bo Li ◽  
Xiangrong Song ◽  
Yu Zheng ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Large Scale ◽  
Film Formation ◽  
Low Cost ◽  
Amphiphilic Polymer ◽  
Target Drug Delivery ◽  
H Nmr ◽  
Target Drug

An amphiphilic polymer RGD-PEG-Chol which can be produced in large scale at a very low cost has been synthesized successfully. The synthesized intermediates and final products were characterized and confirmed by1H nuclear magnetic resonance spectrum (1H NMR) and Fourier transform infrared spectrum (FT-IR). The paclitaxel- (PTX-) loaded liposomes based on RGD-PEG-Chol were then prepared by film formation method. The liposomes had a size within 100 nm and significantly enhanced the cytotoxicity of paclitaxel to B16F10 cell as demonstrated by MTT test (IC50= 0.079 μg/mL of RGD-modified PTX-loaded liposomes compared to 9.57 μg/mL of free PTX). Flow cytometry analysis revealed that the cellular uptake of coumarin encapsulated in the RGD-PEG-Chol modified liposome was increased for HUVEC cells. This work provides a reasonable, facile, and economic approach to prepare peptide-modified liposome materials with controllable performances and the obtained linear RGD-modified PTX-loaded liposomes might be attractive as a drug delivery system.

RGD Peptide-Based Target Drug Delivery of Doxorubicin Nanomedicine

2017 ◽  
Vol 78 (6) ◽  
pp. 283-291 ◽  
Author(s):  
Yuan Sun ◽  
Chen Kang ◽  
Fei Liu ◽  
You Zhou ◽  
Lei Luo ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Rgd Peptide ◽  
Target Drug Delivery ◽  
Target Drug

scholarly journals Therapeutic nanomedicine surmounts the limitations of pharmacotherapy

Open Medicine ◽  
2017 ◽  
Vol 12 (1) ◽  
pp. 271-287 ◽  
Author(s):  
Arome Odiba ◽  
Victoria Ottah ◽  
Comfort Ottah ◽  
Ogechukwu Anunobi ◽  
Chimere Ukegbu ◽  
...  
Keyword(s):  
Cytotoxic Effect ◽  
Unique Property ◽  
The Body ◽  
Regulatory Agencies ◽  
Therapeutic Effects ◽  
Genetic Therapy ◽  
Target Drug Delivery ◽  
Target Drug ◽  
And Control ◽  
Manipulation And Control

AbstractScience always strives to find an improved way of doing things and nanoscience is one such approach. Nanomaterials are suitable for pharmaceutical applications mostly because of their size which facilitates absorption, distribution, metabolism and excretion of the nanoparticles. Whether labile or insoluble nanoparticles, their cytotoxic effect on malignant cells has moved the use of nanomedicine into focus. Since nanomedicine can be described as the science and technology of diagnosing, treating and preventing diseases towards ultimately improving human health, a lot of nanotechnology options have received approval by various regulatory agencies. Nanodrugs also have been discovered to be more precise in targeting the desired site, hence maximizing the therapeutic effects, while minimizing side-effects on the rest of the body. This unique property and more has made nanomedicine popular in therapeutic medicine employing nanotechnology in genetic therapy, drug encapsulation, enzyme manipulation and control, tissue engineering, target drug delivery, pharmacogenomics, stem cell and cloning, and even virus-based hybrids. This review highlights nanoproducts that are in development and have gained approval through one clinical trial stage or the other.

scholarly journals Bone Marrow Regeneration Using Adipose-Derived Stem Cells

2006 ◽  
Vol 73 (1) ◽  
pp. 45-47 ◽  
Author(s):  
Rei Ogawa ◽  
Hiroshi Mizuno ◽  
Hiko Hyakusoku ◽  
Takashi Shimada
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Adipose Derived Stem Cells ◽  
Bone Marrow Regeneration
Sign in / Sign up

Export Citation Format

Share Document